Last update: Nov. 25, 2014

Эноксапарин Натрий

Very Low Risk for breastfeeding


Safe. Compatible.
Not risky for breastfeeding or infant.

This is a Heparin with low molecular weight

There is published evidence of a lack of anti-coagulant activity in the serum of breastfed infants whose mothers were treated with Enoxaparin.

The high molecular weight of the so-called standard or non-fragmented Heparin and others called low weight Heparins makes that excretion into breast milk very unlikely.

There is scientific proof on the lack of excretion of Dalteparin into breast milk.

In addition, Heparin derived drugs are inactivated in the gut and they are not absorbed at all, hence, oral bioavailability is nil.

The risk of Heparin-induced Thrombocytopenia and Osteoporosis is lower with low weight Heparin among treated adults.

Alternatives

We do not have alternatives for Эноксапарин Натрий since it is relatively safe.

Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Эноксапарин Натрий is also known as Enoxaparin Sodium. Here it is a list of alternative known names::


Group

Эноксапарин Натрий belongs to this group or family:

Tradenames

Main tradenames from several countries containing Эноксапарин Натрий in its composition:

Pharmacokinetics

Variable Value Unit
Bioavailability 0 %
Molecular weight 4.500 (3.800 - 5.000) daltons
VD 0,1 l/Kg
Tmax 1 - 5 hours
T1/2 4 - 5 hours

References

  1. Noviani M, Wasserman S, Clowse ME. Breastfeeding in mothers with systemic lupus erythematosus. Lupus. 2016 Abstract
  2. Ozdemir D, Tam AA, Dirikoc A, Ersoy R, Cakir B. Postpartum osteoporosis and vertebral fractures in two patients treated with enoxaparin during pregnancy. Osteoporos Int. 2014 Abstract
  3. Fuller KP, Turner G, Polavarapu S, Prabulos AM. Guidelines for use of anticoagulation in pregnancy. Clin Lab Med. 2013 Abstract
  4. Yurdakök M. Fetal and neonatal effects of anticoagulants used in pregnancy: a review. Turk J Pediatr. 2012 Abstract Full text (link to original source) Full text (in our servers)
  5. Middeldorp S. How I treat pregnancy-related venous thromboembolism. Blood. 2011 Abstract Full text (link to original source) Full text (in our servers)
  6. Rath W. [Thromboprophylaxis during pregnancy and the puerperium: highlights from current guidelines]. Z Geburtshilfe Neonatol. 2010 Abstract
  7. Lindhoff-Last E, Bauersachs R. Heparin-induced thrombocytopenia-alternative anticoagulation in pregnancy and lactation. Semin Thromb Hemost. 2002 Abstract
  8. Wautrecht JC. [Which anticoagulants?]. Rev Med Brux. 2002 Abstract
  9. Richter C, Sitzmann J, Lang P, Weitzel H, Huch A, Huch R. Excretion of low molecular weight heparin in human milk. Br J Clin Pharmacol. 2001 Abstract Full text (link to original source) Full text (in our servers)
  10. Lindhoff-Last E, Willeke A, Thalhammer C, Nowak G, Bauersachs R. Hirudin treatment in a breastfeeding woman. Lancet. 2000 Abstract
  11. Janssen NM, Genta MS. The effects of immunosuppressive and anti-inflammatory medications on fertility, pregnancy, and lactation. Arch Intern Med. 2000 Abstract Full text (link to original source) Full text (in our servers)
  12. Bates SM, Ginsberg JS. Anticoagulants in pregnancy: fetal effects. Baillieres Clin Obstet Gynaecol. 1997 Abstract
  13. Guillonneau M, de Crepy A, Aufrant C, Hurtaud-Roux MF, Jacqz-Aigrain E. [Breast-feeding is possible in case of maternal treatment with enoxaparin]. Arch Pediatr. 1996 Abstract
  14. Kandrotas RJ. Heparin pharmacokinetics and pharmacodynamics. Clin Pharmacokinet. 1992 Abstract
  15. Wunderer G, Müller G. [Osteoporosis and pre- and postpartal heparin therapy]. Geburtshilfe Frauenheilkd. 1990 Abstract
  16. Ginsberg JS, Hirsh J. Optimum use of anticoagulants in pregnancy. Drugs. 1988 Abstract
  17. Harenberg J, Leber G, Zimmermann R, Schmidt W. [Prevention of thromboembolism with low-molecular weight heparin in pregnancy]. Geburtshilfe Frauenheilkd. 1987 Abstract
  18. Estes JW. Clinical pharmacokinetics of heparin. Clin Pharmacokinet. 1980 Abstract

Total visits

1,293

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write to us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine from United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM